Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The available research on dulaglutide includes several recent studies and completed clinical trials, though many focus on broader GLP-1 receptor agonist research rather than dulaglutide specifically.
Recent Research Studies
A 2026 pilot study published in Frontiers in Endocrinology directly compared dulaglutide with empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes patients. This randomized trial included exploratory metabolomic and microbiome analyses, though specific sample sizes and detailed results are not provided in the available evidence.
Several broader studies examined GLP-1 receptor agonists as a class. A 2026 systematic review and meta-analysis in BMC Ophthalmology assessed diabetic retinopathy progression risk with GLP-1 receptor agonists, while another meta-analysis in Pharmacological Research evaluated GLP-1 receptor agonist therapy in children and adolescents with obesity, examining cardiometabolic efficacy and safety profiles through network meta-analysis methodology.
Additional 2026 research includes a target trial emulation study in Annals of Internal Medicine comparing GLP-1 receptor agonists with oral agents for insulin discontinuation in type 2 diabetes, and narrative reviews positioning newer agents like orforglipron among existing GLP-1 receptor agonist benchmarks.
Clinical Trials
Key completed trials include NCT01584232, a Phase 3 study specifically examining dulaglutide in Japanese participants with type 2 diabetes mellitus. A Phase 1 study (NCT01253304) evaluated single-dose dulaglutide (LY2189265) in subjects with varying degrees of hepatic impairment.
The recently completed SURPASS-SWITCH trial (NCT05564039) was a Phase 4 study investigating tirzepatide in adults with type 2 diabetes switching from dulaglutide. Additional Phase 4 research (NCT05005741) compared glucose control and weight loss effects between beinaglutide and dulaglutide in type 2 diabetes patients with overweight or obesity, though the current status is unknown.
Note: This synthesis is limited by the available evidence provided. Detailed results, sample sizes, and specific outcomes from most studies are not included in the source material. For comprehensive clinical decision-making, consult complete published studies and current prescribing information.